No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 28
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Passage Bio, Inc. (PASG) stock was $4.03 as of Oct 6, 2026, 1:33 PM EDT, down 1.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -48.4% · 3-year avg -31.4%/yr · 5-year avg -53.2%/yr
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system.
Biotechnology · Philadelphia, PA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-2.44
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.44
vs Estimate
$-2.27
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PASG | $12.95M | $4.03 | -1.47% | -48.39% | -53.23% | N/A | N/A |
| 2CLRB | $12.94M | $1.62 | -2.99% | -49.83% | -60.51% | -55.35% | vs PASG |
| 3INAB | $13.14M | $1.37 | -3.52% | -40.44% | -62.88% | N/A | vs PASG |
| 4CTSO | $12.73M | $4.05 | +2.14% | -79.67% | -52.26% | -28.72% | vs PASG |
| 5BFRG | $12.71M | $0.69 | +15.44% | -58.58% | N/A | N/A | vs PASG |
| 6DARE | $12.57M | $0.84 | -0.50% | -61.15% | -46.35% | -39.10% | vs PASG |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$15.50
+284.6% upside
Low
$8.00
Current
$4.03
High
$23.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.75 | $-2.44 | $-2.13 | 2 |
| Quarter ending Dec 2026 | $-3.13 | $-2.55 | $-1.97 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-10.41 | $-9.78 | $-9.15 | 2 |
| FY 2027 | $-10.70 | $-10.20 | $-9.69 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $2.00M | $2.00M | $2.00M | 4 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $45.01M |
| $45.01M |
| $45.01M |
| 3 |
